GlassScriptPhysician profile
Josmine Bernadin
NPI 1427560127
$2,680.06
in general payments reported to CMS, 2019-2025
26 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $52.70 · 2023: $228 · 2024: $572 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,454.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $543.88 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $255.48 | 2024-2025 | |
| Abbvie INC. | $235.01 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.71 | 2024-2025 | Jardiance, Ofev |
| Exact Sciences Corporation | $193.66 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $132.83 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $127.21 | 2025 | Auvelity |
| Dexcom, INC. | $116.97 | 2021-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $105.70 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $104.71 | 2022-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $103.55 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.52 | 2025 | Caplyta |
| Lundbeck LLC | $73.19 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $58.76 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Sumitomo Pharma America, INC. | $45.71 | 2025 | Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.72 | 2023-2024 | |
| Medtronic, INC. | $36.44 | 2025 | Inceptiv |
| Idorsia Pharmaceuticals US INC | $35.83 | 2023 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $35.00 | 2025 | Uptravi, Opsynvi |
| Abbott Laboratories | $31.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.06 | 2025 | Trintellix |
| Scilex Pharmaceuticals INC. | $22.58 | 2025 | |
| Cipher Pharmaceuticals US LLC | $18.47 | 2025 | Natroba, Spinosad |
| Astellas Pharma US INC | $17.83 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $15.45 | 2021 | |
| Clarus Therapeutics INC. | $7.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josmine Bernadin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.